Q-omics provides the consensus-scored OR2A7 profile across patient tissues and cancer cell-line models. OR2A7 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in READ. Among the 18 cancer types available for tumor–normal comparison, OR2A7 is differentially expressed in 6, with the highest sampling consensus in THCA. Additionally, OR2A7 RNA expression shows 16,567 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight READ, THCA, and THYM as cancer lineages where OR2A7 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for OR2A7 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes OR2A7 survival associations across molecular data types. OR2A7 RNA expression shows survival associations in the most cancer types (27), followed by mutation status (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible OR2A7 RNA expression–survival associations across cancer types. High OR2A7 expression shows unfavorable associations in DLBC and LAML, but favorable associations in READ, MESO, ESCA and SCLC. The READ Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .002). Together, the overview and detailed table identify READ as the clearest survival context for OR2A7 RNA expression.
This table summarizes OR2A7 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for OR2A7. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. OR2A7 shows lower tumor expression in THCA, COAD, KIRC, BRCA and KICH and higher tumor expression in STAD. The THCA box plot shows higher OR2A7 RNA expression in normal versus tumor tissue (log2 FC = −0.923, t-test p < 0.001).
This table shows molecular features associated with OR2A7 in patient tissues and cancer cell lines. In patient samples, OR2A7 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, OR2A7 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in PANCREAS and UPPER_AERODIGESTIVE_TRACT.
